Kimberly-Clark to buy Tylenol maker Kenvue for nearly $50 billion
Manufacturing giant Kimberly-Clark is set to acquire Kenvue, the maker of Tylenol, for $48.7 billion. CBS News MoneyWatch correspondent Kelly O'Grady ...
Last updated: 2025-11-04 02:56:25 ET
Manufacturing giant Kimberly-Clark is set to acquire Kenvue, the maker of Tylenol, for $48.7 billion. CBS News MoneyWatch correspondent Kelly O'Grady ...
                                
                                                        These are the stocks posting the largest moves midday.
One of the biggest mergers of the year, worth $49 billion, comes just weeks after the Trump administration linked the common painkiller to autism, which the company is fighting.
                                
                                                        Kimberly-Clark is buying Tylenol maker Kenvue in a cash and stock deal worth about $48.7 billion, creating a massive consumer health goods company.
                                
                                                        These are some of the stocks posting the largest moves in premarket trading.
Kenvue’s stock, which had hit a record low in recent weeks, was headed for its best day ever while Kimberly-Clark’s stock tumbled.
                                
                                                        Kimberly-Clark is buying Tylenol maker Kenvue in an approximately $48.7 billion cash-and-stock deal, creating a massive consumer health goods company
                                
                                                        The combined company would bring together brands like Huggies and Kleenex with the likes of Band-Aid and Tylenol.
Kimberly-Clark is buying Tylenol maker Kenvue in an approximately $48.7 billion cash-and-stock deal, creating a massive consumer health goods company.
                                
                                                        The owner of Kleenex and Huggies will acquire the embattled company, which has fought claims by the Trump administration that a common pain reliever i...